A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Spatial-spectral structured sparse low-rank representation for hyperspectral image super-resolution

Hyperspectral image super-resolution by fusing high-resolution multispectral image (HR-MSI) and low-resolution hyperspectral image (LR-HSI) aims at reconstructing high resolution spatial-spectral information of the scene. Existing methods mostly based on spectral unmixing and sparse representation are often developed from a low-level vision task perspective, they cannot sufficiently make use of the spatial and spectral priors available from higher-level analysis. To this issue, this paper proposes a novel HSI super-resolution method that fully considers the spatial/spectral subspace low-rank relationships between available HR-MSI/LR-HSI and latent HSI. Specifically, it relies on a new subspace clustering method named "structured sparse low-rank representation" (SSLRR), to represent the data samples as linear combinations of the bases in a given dictionary, where the sparse structure is induced by low-rank factorization for the affinity matrix. Then we exploit the proposed SSLRR model to learn the SSLRR along spatial/spectral domain from the MSI/HSI inputs. By using the learned spatial and spectral low-rank structures, we formulate the proposed HSI super-resolution model as a variational optimization problem, which can be readily solved by the ADMM algorithm. Compared with state-of-the-art hyperspectral super-resolution methods, the proposed method shows better performance on three benchmark datasets in terms of both visual and quantitative evaluation